Curr Med Chem. 2017 Jul 4. doi: 10.2174/0929867324666170704121800. [Epub ahead of print]
Small molecule inhibitors of hepatitis B virus nucleocapsid assembly: a new approach to treat chronic HBV infection.Yang L1, Lu M2.
Author information
1Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai. China.2Institute of Virology, University Hospital Essen, University Duisburg Essen, Essen. Germany.
AbstractHepatitis B virus (HBV) infection is still a major health problem worldwide. The current available antiviral drugs for the treatment of chronic HBV infection do not achieve satisfactory results. Thus, it is desirable to develop novel anti-HBV drugs based the recent advances of basic research on molecular biology of HBV. HBV nucleocapsid assembly is now considered as a potential target of anti-HBV therapy. Structural and functional analysis provided essential insight of molecular interaction of the components of HBV nucleocapsid. Prototypes of small molecule modulators of HBV nucleocapsid assembly were developed and partly tested in clinical phase I. In the present review, the recent advances in HBV molecular biology and approach to develop inhibitors for anti-HBV treatment based on the disruption of viral nucleocapsids by either prevention of assembly or induction of misassembly will be summarized. We will discuss the future concepts of anti-HBV treatment based on such new approaches.
Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
KEYWORDS: Hepatitis B virus; antiviral therapy.; capsid assembly; capsid assembly modulator; core protein; misassembly
PMID:28675991DOI:10.2174/0929867324666170704121800
| 
发表于 2017-7-6 17:30
